News AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 20:00:03 13/03/2026 GMT			5-day change	1st Jan Change
219.68 ^USD	-2.52%		-4.53%	-3.86%

03-10	AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
03-09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE

All News

03-10	AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
03-09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE
03-09	AbbVie Announces Positive Topline Results From A Phase 1 Multiple Ascending Dose Study of ABBV-295	CI
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE
03-09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
03-09	AbbVie's Study of Weight-Loss Drug Outperforms Placebo	MT
03-09	Gubra's partner AbbVie reports positive phase 1 results for ABBV-295	RE
03-09	AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults	PR
03-09	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study	RE
03-05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
03-05	Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating	MT
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
03-04	When Talk of Talks Moves Markets
03-04	Allergan aesthetics highlights medical weight loss (MWL) data and the changing profile of patients	RE
03-04	ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS	PR
03-03	AbbVie Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
03-03	AbbVie to Present at the Leerink Partners Global Healthcare Conference	PR
03-02	AbbVie's Subcutaneous Skyrizi Meets Co-Primary Efficacy Endpoints in Phase 3 Crohn's Trial	MT
03-02	AbbVie announces positive topline results from phase 3 Affirm study evaluating Skyrizi (risankizumab) subcutaneous induction in patients with Crohn's disease	RE
03-02	AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease	PR
03-02	AbbVie Announces Positive Topline Results from Phase 3 Affirm Study Evaluating SKYRIZI®? (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease	CI
02-25	AbbVie Could See Continued Outperformance Despite Market Concerns, RBC Capital Markets Says	MT
02-25	AbbVie files for seven-part notes offering of up to $8 billion	RE
02-24	AbbVie Plans to Launch Offering of Senior Notes	MT
02-24	AbbVie to Present at the TD Cowen 46th Annual Health Care Conference	PR